80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]魏麗珍,陳玉珊,王藝敏.常規(guī)磁共振聯(lián)合多模態(tài)磁共振成像對脫髓鞘假瘤與膠質(zhì)瘤的鑒別診斷[J].福建醫(yī)藥雜志,2024,46(07):8-12.[doi:10.20148/j.fmj.2024.07.003]
　WEI Lizhen,CHEN Yushan,WANG Yimin.Conventional magnetic resonance combined with multimodal magnetic resonance imaging for differential diagnosis of demyelinating pseudotumor and glioma[J].FUJIAN MEDICAL JOURNAL,2024,46(07):8-12.[doi:10.20148/j.fmj.2024.07.003]
點(diǎn)擊復(fù)制

常規(guī)磁共振聯(lián)合多模態(tài)磁共振成像對脫髓鞘假瘤與膠質(zhì)瘤的鑒別診斷()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期數(shù):
2024年07期
頁碼:
8-12
欄目:
臨床研究
出版日期:
2024-11-20

文章信息/Info

Title:
Conventional magnetic resonance combined with multimodal magnetic resonance imaging for differential diagnosis of demyelinating pseudotumor and glioma
文章編號:
1002-2600(2024)07-0008-05
作者:
魏麗珍; 陳玉珊; 王藝敏
福建醫(yī)科大學(xué)附屬漳州市醫(yī)院,漳州 363000
Author(s):
WEI Lizhen;  CHEN Yushan;  WANG Yimin
Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, China
關(guān)鍵詞:
脫髓鞘假瘤;  膠質(zhì)瘤;  磁共振成像
Keywords:
demyelinating pseudotumor;  glioma;  magnetic resonance imaging
分類號:
R445.2
DOI:
10.20148/j.fmj.2024.07.003
文獻(xiàn)標(biāo)志碼:
B
摘要:
目的 探討常規(guī)磁共振與多模態(tài)磁共振對脫髓鞘假瘤診斷的價(jià)值,并分析脫髓鞘假瘤與膠質(zhì)瘤的鑒別診斷要點(diǎn)。方法 回顧性分析我院收治的脫髓鞘假瘤患者61例與膠質(zhì)瘤患者66例的臨床資料、常規(guī)磁共振圖像、多模態(tài)磁共振圖像,評估各影像征象及影像參數(shù)對于疾病診斷的價(jià)值。結(jié)果 脫髓鞘假瘤好發(fā)于年輕女性患者,臨床病程一般較緩慢,容易出現(xiàn)共濟(jì)失調(diào)、運(yùn)動(dòng)障礙等癥狀,較少出現(xiàn)癲癇; 影像上脫髓鞘假瘤占位效應(yīng)一般較輕,容易出現(xiàn)開環(huán)強(qiáng)化、中心靜脈征、側(cè)腦室垂直征等征象; 彌散加權(quán)成像(DWI)上病灶一般表現(xiàn)為不受限/彌散受限或者開環(huán)狀彌散受限; 磁共振波譜成像(MRS)上脫髓鞘假瘤Cho/NAA、Cho/Cr值通常不高,NAA/Cr比值大于膠質(zhì)瘤。膠質(zhì)瘤MRI圖像顯示累及腦皮質(zhì)的比率(80.3%)大于脫髓鞘假瘤累及腦皮質(zhì)的比率(31.1%); 膠質(zhì)瘤DWI顯示大多為閉環(huán)強(qiáng)化; 57.6%的膠質(zhì)瘤會(huì)出現(xiàn)中心結(jié)節(jié)狀的彌散受限; MRS顯示7例脫髓鞘假瘤表現(xiàn)為低灌注,僅有1例表現(xiàn)為高灌注,膠質(zhì)瘤則全部表現(xiàn)為高灌注。結(jié)論 常規(guī)磁共振與多模態(tài)磁共振對脫髓鞘假瘤與膠質(zhì)瘤的鑒別診斷有一定的價(jià)值。
Abstract:
Objective To explore the value of conventional magnetic resonance imaging(MRI)and multimodal MRI in the diagnosis of demyelinating pseudotumor, and to analyze the key points of differential diagnosis between demyelinating pseudotumor and glioma. Methods The clinical data, conventional MRI and multimodal MRI of 61 patients with demyelinating pseudotumor and 66 patients with glioma admitted to our hospital were analyzed retrospectively, and the value of imaging signs and imaging parameters for disease diagnosis was evaluated. Results Demyelinating pseudotumors were more common in young women, and the clinical course was generally slow, with more symptoms such as ataxia and dyskinesia and less epilepsy. On the image, the occupying effect of demyelinating pseudotumor was generally light, and it was easy to show signs such as open ring enhancement, central venous sign and lateral ventricular vertical sign. Lesions on diffusion-weighted imaging(DWI)generally appeared unrestricted/diffuse restriction or open-loop diffuse restriction; The Cho/NAA and Cho/Cr values of demyelinating pseudotumors on magnetic resonance spectroscopy(MRS)were usually not high, and the NAA/Cr ratio was greater than that of gliomas. MRI images of gliomas showed that the proportion of cerebral cortex involvement(80.3%)were greater than that of demyelinating pseudotumor(31.1%). Glioma DWI was often characterized by closed-loop enhancement; 57.6% of gliomas had central nodular diffusion restriction; MRS showed that seven cases of demyelinating pseudotumors showed hypoperfusion, only one case showed hyperperfusion, and all gliomas showed hyperperfusion. Conclusion Conventional MRI and multimodal MRI have certain value in the differential diagnosis of demyelinating pseudotumor and glioma.

參考文獻(xiàn)/References:

[1] PATRIARCA L, TORLONE S, FERRARI F, et al. Is size an essential criterion to define tumefactive plaque? MR features and clinical correlation in multiple sclerosis[J]. The Neuroradiology Journal,2016, 29(5): 384-389.
[2] KATSUSE K, KURIHARA M, SUGIYAMA Y, et al. Apha-sic status epilepticus preceding tumefactive left hemisphere lesion in anti-MOG antibody associated disease[J]. Multiple Sclerosis and Related Disorders,2019, 27: 91-94.
[3] WEINSHENKER B G. Tumefactive demyelinating lesions: characteristics of individual lesions, individual patients, or a unique disease entity?[J]. Multiple Sclerosis(Houndmills, Basingstoke, England),2015, 21(13): 1746-1747.
[4] 戚曉昆,劉建國. 中樞神經(jīng)系統(tǒng)瘤樣脫髓鞘病變診治指南[J]. 中國神經(jīng)免疫學(xué)和神經(jīng)病學(xué)雜志,2017, 24(5): 305-317.
[5] LIN X, YU W Y, LIAUW L, et al. Clinicoradiologic features distinguish tumefactive multiple sclerosis from CNS neoplasms[J]. Neurology Clinical Practice,2017, 7(1): 53-64.
[6] FRENCH H, FONTES-VILLALBA A, MAHARAJ M, et al. Tumefactive multiple sclerosis versus high grade glioma: a diagnostic dilemma[J]. Surgical Neurology International,2022, 13: 146.
[7] JEONG I H, KIM S H, HYUN J W, et al. Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations[J]. Journal of the Neurological Sciences,2015(358): 118-124.
[8] YIU E M, LAUGHLIN S, VERHEY L H, et al. Clinical and magnetic resonance imaging(MRI)distinctions between tumefactive demyelination and brain tumors in children[J]. Journal of Child Neurology,2014, 29(5): 654-665.
[9] KOBAYASHI M, SHIMIZU Y, SHIBATA N, et al. Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology[J]. Journal of Neurology,2014, 261(10): 1902-1910.
[10] CORTESE R, MAGNOLLAY L, TUR C, et al. Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD[J]. Neurology,2018, 90(14):1183-1190.
[11] SHARMA R, FISCHER M T, BAUER J, et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination[J]. Acta Neuropathologica,2010, 120(2): 223-236.
[12] CHRONAIOU I, STENSJØEN A L, SJØBAKK T E, et al. Impacts of MR spectroscopic imaging on glioma patient management[J]. Acta Oncologica(Stockholm, Sweden),2014, 53(5): 580-589.
[13] BOLCAEN J, ACOU M, MERTENS K, et al. Structural and metabolic features of two different variants of multiple sclerosis: a PET/MRI study[J]. Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging,2013, 23(3): 431-436.
[14] CHA S, PIERCE S, KNOPP E A, et al. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demye-linating lesions[J]. AJNR American Journal of Neuroradiolo-gy,2001, 22(6): 1109-1116.
[15] JAIN R, ELLIKA S, LEHMAN N L, et al. Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?[J]. Journal of Neuro-oncology,2010, 97(3): 383-388.

備注/Memo

備注/Memo:
基金項(xiàng)目:福建省自然科學(xué)基金資助項(xiàng)目(2021J011409)
通信作者:陳玉珊,Email:[email protected]
更新日期/Last Update: 2024-11-20